PMC:7228307 / 45151-45238 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"811","span":{"begin":44,"end":48},"obj":"Gene"},{"id":"826","span":{"begin":58,"end":77},"obj":"Disease"},{"id":"848","span":{"begin":23,"end":28},"obj":"Mutation"},{"id":"851","span":{"begin":30,"end":35},"obj":"Mutation"}],"attributes":[{"id":"A811","pred":"tao:has_database_id","subj":"811","obj":"Gene:2213"},{"id":"A826","pred":"tao:has_database_id","subj":"826","obj":"MESH:D008659"},{"id":"A848","pred":"tao:has_standard_notation","subj":"848","obj":"p.L234A"},{"id":"A851","pred":"tao:has_standard_notation","subj":"851","obj":"p.L235A"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T77","span":{"begin":58,"end":77},"obj":"Disease"}],"attributes":[{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T793","span":{"begin":12,"end":15},"obj":"http://purl.obolibrary.org/obo/CLO_0052882"},{"id":"T794","span":{"begin":12,"end":15},"obj":"http://purl.obolibrary.org/obo/CLO_0053434"},{"id":"T795","span":{"begin":44,"end":46},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T232","span":{"begin":85,"end":87},"obj":"Chemical"}],"attributes":[{"id":"A232","pred":"chebi_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T220","span":{"begin":68,"end":77},"obj":"http://purl.obolibrary.org/obo/OGMS_0000045"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"811","span":{"begin":44,"end":48},"obj":"Gene"},{"id":"826","span":{"begin":58,"end":77},"obj":"Disease"},{"id":"848","span":{"begin":23,"end":28},"obj":"Mutation"},{"id":"851","span":{"begin":30,"end":35},"obj":"Mutation"}],"attributes":[{"id":"A811","pred":"pubann:denotes","subj":"811","obj":"Gene:2213"},{"id":"A826","pred":"pubann:denotes","subj":"826","obj":"MESH:D008659"},{"id":"A848","pred":"pubann:has_HGVS_notation","subj":"848","obj":"p.L234A"},{"id":"A851","pred":"pubann:has_HGVS_notation","subj":"851","obj":"p.L235A"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T261","span":{"begin":0,"end":87},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T33","span":{"begin":58,"end":77},"obj":"Disease"}],"attributes":[{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005066"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}

{"project":"LitCovid-sentences","denotations":[{"id":"T261","span":{"begin":0,"end":87},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II"}